IVIMEA

IVIMEA specializes in professional musculoskeletal/physical therapy lasers. These devices are intended for clinical use, such as targeted tissue treatment and rehabilitation. The focus is on delivering precise laser therapy for musculoskeletal conditions, ensuring they meet the needs of healthcare providers.

IVIMEA is based in the United States. While the company’s location influences its regulatory framework, it does not inherently determine whether its devices are authorized. Instead, each device’s compliance with applicable regulations—such as FDA requirements—determines its regulatory status. For example, IVIMEA’s devices are listed in the FDA’s Unique Device Identifier (UDI) database.

IVIMEA’s devices fall under Class II classification by the FDA. This classification is assigned based on the device’s intended use and risk level. Class II devices generally require special controls in addition to general controls to ensure safety and effectiveness, such as performance standards or post-market surveillance. The IR-20 laser, for instance, is designed for clinical musculoskeletal therapy, aligning with the criteria for this classification.

Yes, IVIMEA’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. This registry tracks device information to improve transparency, traceability, and post-market surveillance. Listing in the UDI database helps healthcare providers, regulators, and other stakeholders verify device details, such as manufacturer information, model specifications, and regulatory status, ensuring compliance and informed decision-making.

The Class II classification for IVIMEA’s devices indicates that while they pose moderate risk, they still require compliance with specific regulatory controls to ensure safe and effective use. This includes adherence to performance standards, labeling requirements, and potential post-market reporting. Users—such as clinicians or physical therapists—can rely on these controls to confirm the device meets FDA-mandated safety and efficacy criteria before clinical application.